The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 11 - 2024 |
doi: 10.3389/fmed.2024.1402902
A double-edged sword: unusual mul2ple severe infec2ons with pralse2nib. A case report and review of literature
Provisionally accepted- 1 Département d'Oncologie Médicale, Institut universitaire du Cancer de Toulouse Oncopole, Toulouse, France
- 2 Department of digestive oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Toulouse, France
- 3 Department of Medical Oncology, Clinical research Unit, Oncopole Toulouse, France., Toulouse, France
- 4 Department of infectiology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Toulouse, France
- 5 Department of thoracic oncology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France., Toulouse, France
SelecTve RET tyrosine kinase inhibitor, pralseTnib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutaTons or fusions in clinical trials. While the lader focused on the risk of pneumoniTs, there is scarse data regarding other type of infecTous risk on pralseTnib. Herein, we report the case of a 53-year-old paTent with CCDC6-RET fusion neuroendocrine tumor, who achieved parTal response with pralseTnib as fifh line therapy. Of parTcular note, during pralseTnib therapy, his clinical course was complicated by five severe infecTous episodes including two oxygen-requiring pneumonias, two disTnct spondylodisciTs and one pneumocysTs. Our study highlights the increased risk of any type of opportunisTc infecTous event with pralseTnib, but not selpercaTnib, probably caused by offtarget JAK1/2 inhibiTon.
Keywords: PralseTnib, RET inhibitor, infecton, JAK/STAT, case report
Received: 20 Mar 2024; Accepted: 08 Jul 2024.
Copyright: © 2024 Poumeaud, Jaffrelot, Gomez-Roca, Korakis, Leonardi, Joly, MAZIERES, GUIMBAUD, Fares and Alouani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Emily Alouani, Department of Medical Oncology, Clinical research Unit, Oncopole Toulouse, France., Toulouse, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Marion Jaffrelot
2